利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

36 条记录 (耗时 0.025 秒)

    Process for catalytically producing phosgene
    7.
    发明授权
    Process for catalytically producing phosgene 失效
    催化生产光气的方法

    公开(公告)号：US4133831A

    公开(公告)日：1979-01-09

    申请号：US885605

    申请日：1978-03-13

    申请人： Mitsuo Masaki ,  Susumu Fuzimura

    发明人： Mitsuo Masaki ,  Susumu Fuzimura

    IPC分类号： C01B32/80 ,  A61K31/28 ,  C07F9/02

    CPC分类号： C01B31/00 ,  A61K31/28 ,  C01B31/26 ,  C01B31/28

    摘要： Disclosed is a process for catalytically producing phosgene in a high yield in a solvent. In this process, carbon monoxide gas is brought into contact with a solution containing chlorine and with a catalyst consisting of at least one phosphine chloride compound, so as to cause the carbon monoxide to react with the chlorine. The phosphine chloride catalyst compound can be selected from substituted and unsubstituted trialkylphosphine dichlorides, substituted and unsubstituted tetraalkyldiphosphine tetrachlorides, substituted and unsubstituted alkylphosphorane dichlorides, and substituted and unsubstituted alkylene-bis(alkylphosphine) tetrachlorides.

    摘要翻译： 公开了在溶剂中以高产率催化生产光气的方法。 在该过程中，一氧化碳气体与含氯溶液和由至少一种氯化膦化合物组成的催化剂接触，以使一氧化碳与氯反应。 氯化膦催化剂化合物可以选自取代和未取代的三烷基二氯化膦，取代和未取代的四烷基二膦四氯化物，取代和未取代的烷基二氯化磷，以及取代和未取代的亚烷基 - 二（烷基膦）四氯化物。

    Peptides, and antidementia agents containing the same
    8.
    发明授权
    Peptides, and antidementia agents containing the same 失效
    肽，和含有它们的抗增生剂

    公开(公告)号：US5349050A

    公开(公告)日：1994-09-20

    申请号：US838140

    申请日：1992-02-18

    申请人： Mitsuo Masaki ,  Masaki Uehara ,  Kenji Hirate ,  Yoshikazu Isowa ,  Yoshiaki Sato ,  Yoshiharu Nakashima

    发明人： Mitsuo Masaki ,  Masaki Uehara ,  Kenji Hirate ,  Yoshikazu Isowa ,  Yoshiaki Sato ,  Yoshiharu Nakashima

    IPC分类号： A61K38/00 ,  C07K5/02 ,  C07K5/103 ,  C07K5/117 ,  C07K7/16 ,  A61K31/34 ,  A61K31/02 ,  C07K5/10 ,  C07K7/06

    CPC分类号： C07K5/0202 ,  C07K5/1013 ,  C07K5/1024 ,  C07K7/16 ,  A61K38/00

    摘要： Disclosed is a novel peptide having one of the formulae: ##STR1## (A and B are the amino acids: wherein if A is D- or L-Pro, B is Hat or Cit;if A is D-Pro, B is D-Arg, andif B is D- or L-Arg, A is Sat, Pip, Aze or Arg)Asn-A-L- (D-)Pro-Arg- (Gly)n (A is Set, Thr or Ala, n is 1 or 0)A-Ser-Pip-Arg (A is Pro-Asn-, Asn- or Pro-) ##STR2## (A is cyclopentylcarbonyl, Pro or pGlu; B is Gly or .beta.-Ala, W is a hydrogen atom or a group having the formula:or a peptide having the formula: ##STR3## wherein A and B have the same meanings as mentioned above, respectively pGlu-Asn-Ser-A-B-(Gly)n (A is Aze, D- or L-Pro, Pip or Sat, B is D- or L-Arg, Cit, Hat, Lys or Orn, n is 1 or 0) andPro- (Ash)m-Set-L- (D-)Pro-Arg- (Gly) n (m and n are independently 0 or 1)their functional derivatives, and pharmaceutically acceptable salts thereof.

    摘要翻译： 公开了具有下式之一的新肽：（A和B是氨基酸：其中如果A是D-或L-Pro，B是Hat或Cit;如果A是D-Pro，B是D -Arg，如果B为D-或L-Arg，A为Sat，Pip，Aze或Arg）Asn-AL-（D-）Pro-Arg-（Gly）n（A为Set，Thr或Ala，n （A为Pro-Asn-，Asn-或Pro-）A（A为环戊基羰基，Pro或pGlu; B为Gly或β-Ala，W为氢 原子或具有下式的基团：或具有下式的肽：其中A和B分别具有与上述相同的含义，分别为pGlu-Asn-Ser-AB-（Gly）n（A为Aze，D- 或L-Pro，Pip或Sat，B为D-或L-Arg，Cit，Hat，Lys或Orn，n为1或0）和Pro-（Ash）m-Set-L-（D- Arg-（Gly）n（m和n独立地为0或1）它们的官能衍生物及其药学上可接受的盐。

    Alkylenediamine derivatives
    9.
    发明授权
    Alkylenediamine derivatives 失效
    烷二胺衍生物

    公开(公告)号：US5310902A

    公开(公告)日：1994-05-10

    申请号：US741590

    申请日：1991-08-07

    申请人： Mitsuo Masaki ,  Masaru Satoh ,  Naoya Moritoh ,  Koichi Hashimoto ,  Toshiro Kamishiro ,  Haruhiko Shinozaki

    发明人： Mitsuo Masaki ,  Masaru Satoh ,  Naoya Moritoh ,  Koichi Hashimoto ,  Toshiro Kamishiro ,  Haruhiko Shinozaki

    IPC分类号： C07D295/13 ,  C07D223/00 ,  C07D211/26

    CPC分类号： C07D295/13

    摘要： Novel alkylenediamine derivatives effectively employable glutamate blockers have the formula (I) or (II): ##STR1## wherein each of R.sup.1 and R.sup.6 is an aliphatic hydrocarbon group, an alicyclic hydrocarbon group, an aryl group, or an aralkyl group; each of R.sup.2 and R.sup.7 is an aliphatic hydrocarbon group, an alkoxy group, an aliphatic hydrocarbon group containing an ester bonding, an aliphatic hydrocarbon group containing an ether bonding, or an aryloxy group; each of R.sup.3, R.sup.4, R.sup.5 R.sup.8, R.sup.9 and R.sup.10 is hydrogen, an alkyl group, an alkoxy group, an acyloxy group, an aryl group, an aralkyl group, hydroxyl, a hydroxylalkyl group, halogen, nitrile, nitro, amino, carbamoyl or alkoxycarbonyl; and each of m and n is an integer of 0-3 (m+n does not exceed 3); k is an integer of 1-4; each of p and i is an integer of 2-13; and each of q and j is an integer of 4-7.

    摘要翻译： 新型亚烷基二胺衍生物有效地可用的谷氨酸盐阻滞剂具有式（I）或（II）：其中R 1和R 6各自为脂族烃基，脂环族烃基，芳基 ，或芳烷基; R 2和R 7各自为脂族烃基，烷氧基，含酯键的脂族烃基，含有醚键的脂族烃基或芳氧基; R 3，R 4，R 5，R 9和R 10各自为氢，烷基，烷氧基，酰氧基，芳基，芳烷基，羟基，羟基烷基，卤素，腈，硝基，氨基，氨基甲酰基 或烷氧基羰基; 并且m和n分别为0-3的整数（m + n不超过3）; k是1-4的整数; p和i中的每一个是2-13的整数; 并且q和j中的每一个是4-7的整数。